Skip to content
DataLookout
Menu

NCT04077723

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 83 versions: 34 with changes below, 16 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 18 words
    • Primary and study completion moved earlier from Mar 31, 2027 to Dec 28, 2026
    • Secondary endpoints: details revised at 3 of 24 entries
    • Site details revised at 1 of 35 sites
  2. Minor Trial sites reduced: 44 → 35 locationsv81
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 43 to 44
    v80
  4. Minor Study sites: 41 to 43v78
  5. Minor Study sites: 40 to 41v77
Show 29 earlier versionsHide 29 earlier versions
  1. Minor Study sites: 39 to 40v76
  2. Minor Study sites: 38 to 39v74
  3. Minor Study sites: 37 to 38v73
  4. Minor Site details revised at 1 of 37 sitesv71
  5. Minor Study sites: 35 to 37v68
  6. Minor Study sites: 33 to 35v67
  7. Notable Eligibility criteria shortened, about 6 words
    • Study sites: 17 to 33
    v66
  8. Notable Phase: Phase 1 to Phase 1/2
    • Primary and study completion dates: Mar 31, 2025 to Mar 31, 2027
    • Eligibility criteria expanded, about 31 words
    • Interventions: Glofitamab (Drug), Obinutuzumab (Drug), RO7227166 (Drug), Tocilizumab (Drug) to Englumafusp alfa (Drug), Glofitamab (Drug), Obinutuzumab (Drug), Tocilizumab (Drug)
    v65
  9. Minor Site details revised at 2 of 17 sitesv57
  10. Minor Site details revised at 1 of 17 sitesv55
  11. Minor Site details revised at 3 of 17 sitesv54
  12. Minor Site details revised at 5 of 17 sitesv53
  13. Minor Site details revised at 1 of 17 sitesv52
  14. Minor Site details revised at 2 of 17 sitesv51
  15. Minor Enrollment target: 420 to 498
    • Site details revised at 3 of 17 sites
    v50
  16. Minor Study sites: 16 to 17v49
  17. Minor Site details revised at 1 of 16 sitesv48
  18. Minor Study sites: 15 to 16v47
  19. Minor Site details revised at 3 of 15 sitesv46
  20. Minor Site details revised at 4 of 15 sitesv45
  21. Notable Primary and study completion dates: Jan 5, 2023 to Mar 31, 2025
    • Site details revised at 2 of 15 sites
    v44
  22. Minor Study sites: 14 to 15v43
  23. Minor Site details revised at 1 of 14 sitesv42
  24. Minor Study sites: 13 to 14v40
  25. Minor Study sites: 12 to 13v39
  26. Minor Site details revised at 1 of 12 sitesv38
  27. Minor Enrollment target: 362 to 420
    • Site details revised at 1 of 12 sites
    v37
  28. Minor Site details revised at 2 of 12 sitesv36
  29. Study Status, Contacts/Locationsv34
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Nature and frequency of dose-limiting toxicities (DLTs)
Timeframe: 28 days in Part I and Part II
Proportion of Participants with Adverse Event (AE)
Timeframe: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
Overall Response Rate (ORR)
Timeframe: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
Disease Control Rate (DCR)
Timeframe: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
Duration of Response (DOR)
Timeframe: After end of Study approximately every 3 months until death, loss to follow-up or study termination
Progression-free Survival (PFS)
Timeframe: After end of Study approximately every 3 months until death, loss to follow-up or study termination
Overall Survival (OS)
Timeframe: After end of Study approximately every 3 months until death, loss to follow-up or study termination
Complete Response (CR)
Timeframe: Part III: Up to 9 months or up to 18 months

Secondary (24)

Total exposure (area under the concentration time curve [AUC]) of englumafusp alfa in combination with obinutuzumab and glofitamab
Maximum serum concentration (peak concentration, Cmax) of englumafusp alfa in combination with obinutuzumab and glofitamab
Minimum serum concentration (trough concentration, Cmin) of englumafusp alfa in combination with obinutuzumab and glofitamab
Clearance (CL) of englumafusp alfa in combination with obinutuzumab and glofitamab
Volume of distribution of steady state (Vss) and half-life (t1/2) of englumafusp alfa in combination with obinutuzumab and glofitamab
Show 19 moreShow less
ORR
DCR
DOR
PFS
OS
Proportion of Participants with Adverse Event (AE)
Total exposure (area under the concentration time curve [AUC]) of englumafusp alfa in combination with glofitamab
Maximum serum concentration (peak concentration, Cmax) of englumafusp alfa in combination with glofitamab
Minimum serum concentration (trough concentration, Cmin) of englumafusp alfa in combination with glofitamab
Clearance (CL) of englumafusp alfa in combination with glofitamab
Volume of distribution of steady state (Vss) and half-life (t1/2) of englumafusp alfa in combination with glofitamab Part I/II/III
T-cell and Natural killer (NK)-cell status in blood, using markers of T and NK-cell lineage, function and activation including, but not limited to, CD3, CD8, 41BB, and Ki67 expression
B-cell reduction in blood and tumor tissue
Change from Baseline in englumafusp alfa Anti-Drug Antibody (ADA) Titer
Time to First Complete Response (TFCR)
Time to First Overall Response (TFOR)
Duration of Complete Response (DOCR)
Change from Baseline in Physical Function, Role Function, and Health-Related Quality of Life (HRQoL) Based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Change from Baseline in Physical Function, Role Function, and HRQoL According to the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Lymphoma Scale

Arms and interventions

Part IExperimental

Combination Dose-Escalation: Mixed r/r NHL participants will receive a fixed dose of obinutuzumab up to seven days prior to first administration of englumafusp alfa. Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab in a three-weekly schedule (Q3W).

Part IIExperimental

Combination Dose-Escalation: Mixed r/r participants and participants with mixed r/r mantle cell lymphoma (MCL) and Richters transformation will receive a fixed dose of obinutuzumab seven days prior to first administration of englumafusp alfa. Englumafusp alfa will be administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).

Part IIIExperimental

Dose-Expansion Stage: Participants with r/r diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), high-grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL), and DLBCL arising from FL (transformed FL) will receive englumafusp alfa administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).

Drugs: Englumafusp alfa, Obinutuzumab, Glofitamab, Tocilizumab

Sites

35 sites in 12 countries

China 4, France 4, Italy 4, South Korea 4, United States 4, Denmark 3, Spain 3, Australia 2, Canada 2, New Zealand 2, United Kingdom 2, Belgium 1